Invitation to APASL Hepatology Webinar

BEST publications in “Hepatology International”

Friday, March 31, 2023 at 17:00 (UTC/GMT +08:00) Asia/Beijing

Episode 7 Session 1： “HCC”

It is our great pleasure to invite you to participate in the Asian Pacific Association for the Study of Liver (APASL) Hepatology Webinar Episode 7.

Register at: https://regconf.com/apasl_webinar/

If you have already registered, please click the following URL to join the Webinar.

URL https://zoom.us/join ID 853 5158 0540 Password apasl2023 Please join us! (Complimentary)

Dual targeting of PD‑L1 and PD‑L2 by PCED1B‑AS1 via sponging hsa‑miR‑194‑5p induces immunosuppression in hepatocellular carcinoma

Fan F, Chen K, Lu X, Li A, Liu C, Wu B. Hepatol Int. 2021 Apr;15(2):444-458

https://www.apasl.info/wp-apasl/wp-content/uploads/2023/03/3.-Dual-targeting-of-PD-L1-and-PD-L2-by-PCED1B-AS1-via-sponging-hsa-miR-194-5p-induces-immunosuppression-in-hepatocellular-carcinoma.pdf

Lenvatinib in combination with transarterial chemoembolization

for treatment of unresectable hepatocellular carcinoma (uHCC):

a retrospective controlled study

Fu Z, Li X, Zhong J, Chen X, Cao K, Ding N, Liu L, Zhang X, Zhai J, Qu Z. Hepatol Int. 2021 Jun;15(3):663-675

https://www.apasl.info/wp-apasl/wp-content/uploads/2023/03/5.-Lenvatinib-in-combination-with-transarterial-chemoembolization-for-treatment-of-unresectable-hepatocellular-carcinoma-uHCC-a-retrospective-controlled-study.pdf

Wnt status‑dependent oncogenic role of BCL9 and BCL9L in hepatocellular carcinoma

Huge N, Sandbothe M, Schröder AK, Stalke A, Eilers M, Schäffer V, Schlegelberger B, Illig T, Vajen B, Skawran B. Hepatol Int. 2020 May;14(3):373-384

https://www.apasl.info/wp-apasl/wp-content/uploads/2023/03/8.-Wnt-status-dependent-oncogenic-role-of-BCL9-and-BCL9L-in-hepatocellular-carcinoma.pdf

Please don’t miss it!